SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced two presentations of long-term efficacy and safety data from Study 903E on the company’s leading once-daily anti-HIV medication, Viread® (tenofovir disoproxil fumarate). This clinical trial is an ongoing open-label extension of Gilead’s Study 903, a three-year double-blinded randomized clinical trial that compared once-daily Viread to twice-daily stavudine (d4T), both in combination with lamivudine and efavirenz in treatment-naïve patients. A subset of patients who completed Study 903 were enrolled in Study 903E and received two additional years of treatment with Viread, lamivudine and efavirenz. Long-term data were presented for patients who remained on a Viread-containing regimen for a total of five years and for those who switched from twice-daily stavudine to once-daily Viread upon enrollment in Study 903E. Data from both analyses of Study 903E were presented this week at the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, held September 24-26 in San Francisco (Posters #82 and #29).
